Trial Profile

A Phase 1/2, Open Label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of TAS0728, an Oral Covalent Binding Inhibitor of HER2, in Subjects With Advanced Solid Tumors With HER2 or HER3 Abnormalities

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 09 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TAS-0728 (Primary)
Indications Advanced breast cancer; Biliary cancer; Colorectal cancer; Endometrial cancer; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Rectal cancer; Solid tumours; Urogenital cancer
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Taiho Oncology

09 Dec 2021 Planned End Date changed from 31 Dec 2021 to 30 Jun 2022.
09 Dec 2021 Planned primary completion date changed from 31 Dec 2021 to 30 Jun 2022.
29 Sep 2021 Planned End Date changed from 31 Aug 2021 to 31 Dec 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com